Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
Health
STAT+
Pharmalot
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Introducing Go West: A new newsletter about life sciences on the West Coast

  • Rebecca Robbins

By Rebecca Robbins Nov. 14, 2018

Reprints

This is the first edition of Go West, a new weekly newsletter from STAT. To receive future editions in your inbox, sign up here. And if you like it, tell your friends.

Good morning, and welcome to the first edition of STAT’s West Coast newsletter.

advertisement

My name is Rebecca Robbins, and I’m writing to you from my base in San Francisco. Today and each Wednesday morning, I’ll guide you through the latest news in life sciences, health care, and biotech coming out of the Pacific Time Zone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Rebecca Robbins

Rebecca Robbins

Health Tech Correspondent

Rebecca covers health technology. She is the co-author of the newsletter STAT Health Tech.

Akero’s NASH drug combined with Ozempic cut liver fat…
Akero’s NASH drug combined with Ozempic cut liver fat in small study
How Tennessee is creating new opportunities for doctors trained…
How Tennessee is creating new opportunities for doctors trained outside the U.S.
Combination of two drugs can help treat methamphetamine addiction…
Combination of two drugs can help treat methamphetamine addiction for some, new clinical trial data shows 
FDA oncology head wants advisory panels to keep voting…
FDA oncology head wants advisory panels to keep voting on new drugs
Gilead’s CAR-T therapy prolongs survival in key blood cancer…
Gilead’s CAR-T therapy prolongs survival in key blood cancer trial
Bellerophon Therapeutics trial fails despite innovative digital endpoint
Bellerophon Therapeutics trial fails despite innovative digital endpoint

Recommended Stories